Wiersinga WM, et al. - The goal of the experts was to formulate a predictive score for the development or progression of Graves' orbitopathy (GO) in Graves' hyperthyroidism (GH) in patients with newly diagnosed GH, treated with antithyroid drugs (ATD) for 18 months at 10 participating centers from EUGOGO in 8 European countries. The development of GO would be found in 15% cases (13% mild, 2% moderate-to-severe) during subsequent treatment with ATD for 18 months among subjects without GO at diagnosis. It was discovered that a predictive score called PREDIGO composed of four baseline determinants, appeared to be better in speculating those patients not developing obvious GO compared to those who would.